Amneal Pharmaceuticals, Inc. (AMRX) Financial Statements (2025 and earlier)

Company Profile

Business Address
,
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in millions)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9226248341151213
Cash and cash equivalent9226248341151213
Restricted cash and investments899625
Receivables10775707669636529
Inventory, net of allowances, customer advances and progress billings581531489491381457
Inventory581531489491381457
Prepaid expense434241343538
Contract with customer, asset, after allowance for credit loss221212
Other undisclosed current assets64227258441
Total current assets:1,3781,4121,5201,5521,2101,287
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization   645961
Operating lease, right-of-use asset4356605970
Property, plant and equipment448470514478478544
Intangible assets, net (including goodwill)1,4891,6951,7601,8271,8022,081
Goodwill599599593523420426
Intangible assets, net (excluding goodwill)8901,0961,1671,3051,3831,655
Other noncurrent assets5610321324468
Other undisclosed noncurrent assets5963   373
Total noncurrent assets:2,0952,3882,4202,4542,4563,066
TOTAL ASSETS:3,4733,7993,9404,0063,6664,353
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:  538583614507514
Taxes payable369 
Employee-related liabilities62593677
Accounts payable  166131153103115
Accrued liabilities  13172807766
Other undisclosed accounts payable and accrued liabilities  241316316283257
Debt343031442121
Estimated litigation liability77107    
Due to related parties2488618
Other undisclosed current liabilities735751511150
Total current liabilities:847753677677550554
Noncurrent Liabilities
Long-term debt and lease obligation2,3862,5922,6802,7352,6092,670
Long-term debt, excluding current maturities2,3862,5922,6802,7352,6092,631
Capital lease obligations39
Liabilities, other than long-term debt1114787864039
Deferred compensation liability, classified11     
Estimated litigation liability049    
Due to related parties1048   
Other liabilities  8739864039
Other undisclosed noncurrent liabilities16799112151120194
Total noncurrent liabilities:2,5652,8382,8792,9722,7692,903
Total liabilities:3,4113,5903,5563,6493,3193,456
Temporary equity, including noncontrolling interest41251712  
Equity
Equity, attributable to parent, including:20298360303232505
Additional paid in capital539692658628607530
Accumulated other comprehensive income (loss)(32)10(25)(41)(0)(8)
Accumulated deficit(490)(406)(276)(287)(378)(21)
Other undisclosed equity, attributable to parent333333
Equity, attributable to noncontrolling interest0(114)742115392
Total equity:20184367345347896
TOTAL LIABILITIES AND EQUITY:3,4733,7993,9404,0063,6664,353

Income Statement (P&L) ($ in millions)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Revenues2,3942,2122,0941,9931,6261,663
Cost of revenue
(Cost of Product and Service Sold)
(1,573)(1,416)(1,302)(1,330)(1,147)(947)
Other undisclosed gross profit  (11)(23)(35)(126) 
Gross profit:821785769628353716
Operating expenses(632)(884)(603)(537)(602)(533)
Other operating income, net 14    
Other undisclosed operating income (loss)140(14)  (203)
Operating income (loss):204(95)15391(249)(20)
Nonoperating income (expense)(245)(153)(121)(127)28(183)
Investment income, nonoperating    07(3)
Gain (loss), foreign currency transaction, before tax2(12)(0)16(5)(20)
Interest and debt expense(5)(5)(5)(9)(6)(6)
Income (loss) from continuing operations before equity method investments, income taxes:(45)(253)27(44)(227)(209)
Other undisclosed income from continuing operations before income taxes555966
Income (loss) from continuing operations before income taxes:(40)(248)31(36)(220)(203)
Income tax expense (benefit)(8)(7)(11)104(383)1
Income (loss) from continuing operations:(49)(255)2069(604)(201)
Income (loss) before gain (loss) on sale of properties:2069(604)(201)
Other undisclosed net income   5   
Net income (loss):(49)(255)2069(604)(201)
Net income (loss) attributable to noncontrolling interest(35)125(10)2224233
Other undisclosed net income (loss) attributable to parent 5(141)3  149
Net income (loss) attributable to parent:(79)(271)1391(362)(20)
Preferred stock dividends and other adjustments  (0)   (1)
Other undisclosed net income (loss) available to common stockholders, basic (5)141(3)   
Net income (loss) available to common stockholders, diluted:(84)(130)1191(362)(21)

Comprehensive Income ($ in millions)

12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
Net income (loss):(49)(255)2069(604)(201)
Comprehensive income (loss):(49)(255)2069(604)(201)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest(25)90(27)6523236
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(53)7034(84)19142
Comprehensive income (loss), net of tax, attributable to parent:(127)(95)2750(353)(23)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: